Literature DB >> 32391971

Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.

Eswar Shankar1,2, Mitali Pandey1,2, Shiv Verma1,2, Ata Abbas1,2, Mario Candamo3, Rajnee Kanwal1,2, Sanjeev Shukla1,2, Gregory T MacLennan4, Sanjay Gupta1,2,5,6,7.   

Abstract

Maspin repression is frequently observed in prostate cancer; however, the molecular mechanism(s) causing the loss is not completely understood. Here, we demonstrate that inhibition of class I histone deacetylases (HDACs) mediates re-expression of maspin which plays an essential role in suppressing proliferation and migration capability in prostate cancer cells. Human prostate cancer LNCaP and DU145 cells treated with HDAC inhibitors, sodium butyrate, and trichostatin A, resulted in maspin re-expression. Interestingly, an exploration into the molecular mechanisms demonstrates that maspin repression in prostate tumor and human prostate cancer cell lines occurs via epigenetic silencing through an increase in HDAC activity/expression, independent of promoter DNA hypermethylation. Furthermore, transcriptional activation of maspin was accompanied with the suppression of HDAC1 and HDAC8 with significant p53 enrichment at the maspin promoter associated with an increase in histone H3/H4 acetylation. Our results provide evidence of maspin induction as a critical epigenetic event altered by class I HDACs in the restoration of balance to delay proliferation and migration ability of prostate cancer cells.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  epigenetics; histone acetylation; histone deacetylases; maspin; metastasis; prostate cancer

Mesh:

Substances:

Year:  2020        PMID: 32391971      PMCID: PMC7436196          DOI: 10.1002/mc.23214

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  48 in total

1.  Methylation matters: a new spin on maspin.

Authors:  Joseph F Costello; Paula M Vertino
Journal:  Nat Genet       Date:  2002-06       Impact factor: 38.330

2.  P53 regulated maspin protein expression determines recurrence-free survival of patients with localised prostate cancer.

Authors:  S Machtens; M Kuczyk; J Serth; U Jonas
Journal:  Prostate Cancer Prostatic Dis       Date:  2000-12       Impact factor: 5.554

3.  Loss of maspin expression contributes to a more invasive potential in malignant melanoma.

Authors:  Alexandra E Denk; Marcus Bettstetter; Peter J Wild; Keith Hoek; Frauke Bataille; Wolfgang Dietmaier; Anja K Bosserhoff
Journal:  Pigment Cell Res       Date:  2007-04

4.  The role of acetylation sites in the regulation of p53 activity.

Authors:  Yun Wang; Yaqi Chen; Qiang Chen; Xiuyuan Zhang; Hongye Wang; Zhonghua Wang; Jian Wang; Chunyan Tian
Journal:  Mol Biol Rep       Date:  2019-11-04       Impact factor: 2.316

Review 5.  An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis.

Authors:  Brigitte Goulet; Gabriel Chan; Ann F Chambers; John D Lewis
Journal:  Biochem Cell Biol       Date:  2011-11-02       Impact factor: 3.626

6.  Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin.

Authors:  Xiaohua Li; Shuping Yin; Yonghong Meng; Wael Sakr; Shijie Sheng
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

7.  Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases.

Authors:  Vijay S Thakur; Karishma Gupta; Sanjay Gupta
Journal:  Int J Oncol       Date:  2012-04-26       Impact factor: 5.650

8.  p53 regulates the expression of the tumor suppressor gene maspin.

Authors:  Z Zou; C Gao; A K Nagaich; T Connell; S Saito; J W Moul; P Seth; E Appella; S Srivastava
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

9.  Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression.

Authors:  Marc M Oshiro; George S Watts; Ryan J Wozniak; Damian J Junk; Jose L Munoz-Rodriguez; Frederick E Domann; Bernard W Futscher
Journal:  Oncogene       Date:  2003-06-05       Impact factor: 9.867

10.  Methylation-induced silencing of maspin contributes to the proliferation of human glioma cells.

Authors:  Liang Xu; Hongyuan Liu; Ju Yu; Zhongyong Wang; Qing Zhu; Zongping Li; Qi Zhong; Shuyu Zhang; Mingqi Qu; Qing Lan
Journal:  Oncol Rep       Date:  2016-05-04       Impact factor: 3.906

View more
  6 in total

Review 1.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

Review 2.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088

3.  In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy.

Authors:  Chung-Jen Chiang; Yan-Hong Hong
Journal:  Sci Rep       Date:  2021-09-13       Impact factor: 4.379

Review 4.  Pathological Role of HDAC8: Cancer and Beyond.

Authors:  Ji Yoon Kim; Hayoung Cho; Jung Yoo; Go Woon Kim; Yu Hyun Jeon; Sang Wu Lee; So Hee Kwon
Journal:  Cells       Date:  2022-10-09       Impact factor: 7.666

5.  Molecular Characterization and Clinical Relevance of Lysine Acetylation Regulators in Urological Cancers.

Authors:  Jian Zhang; Chunning Zhang; Huali Jiang; Hualong Jiang; Yawei Yuan
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

6.  miR-142-5p Inhibits Cell Invasion and Migration by Targeting DNMT1 in Breast Cancer.

Authors:  Hui Li; Han-Han Li; Qian Chen; Yu-Yang Wang; Chang-Chang Fan; Yuan-Yuan Duan; You Huang; Hui-Min Zhang; Jia-Peng Li; Xiao-Yu Zhang; Yuan Xiang; Chao-Jiang Gu; Li Wang; Xing-Hua Liao; Tong-Cun Zhang
Journal:  Oncol Res       Date:  2021-07-28       Impact factor: 5.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.